Isavuconazonium Sulfate Patent Expiration

Isavuconazonium Sulfate was first introduced by Astellas Pharma Us Inc in its drug Cresemba on Mar 6, 2015.


Isavuconazonium Sulfate Patents

Given below is the list of patents protecting Isavuconazonium Sulfate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Cresemba US10206879

(Pediatric)

Active ingredient containing stabilised solid forms and method for the production thereof Mar 14, 2028 Astellas
Cresemba US10603280

(Pediatric)

Active ingredient containing stabilised solid medicinal forms and methods for the production thereof Mar 14, 2028 Astellas
Cresemba US10206879 Active ingredient containing stabilised solid forms and method for the production thereof Sep 14, 2027 Astellas
Cresemba US10603280 Active ingredient containing stabilised solid medicinal forms and methods for the production thereof Sep 14, 2027 Astellas
Cresemba US6812238

(Pediatric)

N-substituted carbamoyloxyalkyl-azolium derivatives May 01, 2026 Astellas
Cresemba US10812238 Configurable reference signals Oct 31, 2025 Astellas
Cresemba US6812238 N-substituted carbamoyloxyalkyl-azolium derivatives Oct 31, 2025 Astellas
Cresemba US7459561 N-substituted carbamoyloxyalkyl-azolium derivatives Oct 31, 2020

(Expired)

Astellas



Isavuconazonium Sulfate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List